The Seed Investor
Early Stage Investing
Join our Newsletter  Hand-picked cannabis stocks, news & alerts straight to your inbox (100% FREE!)
  •  
  • Cannabis News
  • Marijuana Industry
  • Marijuana Investing
  • Psychedelics
  • Featured Companies
  • TSI Exclusive
  • About
    • Overview
    • Disclaimer
    • Advertise
    • Privacy Policy

Trending Now

  • MCUR’s $10 Million Financing Triples Cash Reserves, Powers Operations Strategies
  • Mind Cure Establishes Psychedelic Compound Research Program
  • Compass Pathways Files For NASDAQ Listing: Psychedelics Game-Changer
  • MindMed And Eleusis Lead The Way In Psychedelics Micro-Dosing Research
  • Why Psychedelics Micro-Dosing Applications Have The Inside Track On Commercialization
  • Cannabis Sales Soar 48% In 2019, 2020 Looking Even Stronger
Psychedelic Stocks
Exploring the companies and themes that make up this emerging and exciting new sector

Optimi Health Completes Expansion Of On-Site Analytical Laboratory

2022-05-11 PSW Editor

Optimi Health announces the completion of its previously announced lab expansion for its Princeton, British Columbia facility.

COMPASS Pathways plc announces first quarter 2022 financial results and business highlights

2022-05-10 PSW Editor

Compass Pathways reports its Q1 for 2022. Net loss of $21.2 million on increased R&D expenses. Cash position of $243.7 million.

Psychedelic Medicine: The New Frontier In Healthcare, The Big Opportunity In Biopharma

2022-05-10 Jeff Nielson

A plethora of drug R&D opportunities. A multitude of badly under-served healthcare treatment markets. A medical "miracle"; an investment pot of gold.

New York Lawmakers Discuss Competing Psychedelics Reform Bills Ahead Of Key Deadline

2022-05-06 Noah Daly

With just a month left before the end of New York’s legislative session, lawmakers sponsoring differing psychedelics reform legislation recently participated in a discussion on the path forward for psilocybin in the Empire State.

PharmaTher Announces Grant of U.S. Patent on Formulation and Production Process of Ketamine and Ketamine Analogs

2022-05-05 PSW Editor

Pharmather announces receiving a patent from the USPTO for its "ketamine flow synthesis". Pharmather has exclusive worldwide development and commercial rights to this IP.

Wesana Announces Singular Focus on Drug Development Prompting a Strategic Review of its Clinics and Other Care Delivery Assets

2022-05-05 PSW Editor

Wesana announces a strategic review of its assets and a decision to focus on drug development.

Optimi Health Granted Amendment To Controlled Substances Dealer’s Licence

2022-05-04 PSW Editor

Optimi Health announces receiving amendment to Health Canada's Dealer's License that will allow expand cultivation and research use of psilocybin and psilocin.

Ketamine Wellness Centers (KWC) Introduces NAD+ Infusion Therapy

2022-05-04 PSW Editor

Delic Holdings announces a new health & wellness therapy offered through its Ketamine Wellness Centers mental health clinics.

MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT

2022-05-04 PSW Editor

Mydecine announces raising $1,693,434.60 in addition to gross proceeds of $333,333.35 announced on March 22, 2022.

Wesana Health Reports Q4 2021 Financial Results and Provides Subsequent Period Highlights

2022-05-04 PSW Editor

Wesana reports its Q4 2021 financial results and announces closing of a financing.

Awakn Life Sciences Reports Fiscal Fourth Quarter and Fiscal Year January 31, 2022, Results

2022-05-02 PSW Editor

Awakn Life Sciences reports fourth quarter and full-year results for its fiscal year ending January 31, 2022. Annual revenues of CAD$236,037.

Optimi Health Opens Canada’s Largest GMP-Grade Licensed Psilocybin Cultivation Facility

2022-04-29 PSW Editor

Optimi Health announces the opening of Canada's largest GMP-grade psilocybin cultivation operating, including a 10,000 square foot production facility.

  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • ...
  • 73
  • Next
Join our Newsletter
 Hand-picked cannabis stocks, news & alerts straight to your inbox (100% FREE!)

The Seed Investor Exclusive

MCUR’s $10 Million Financing Triples Cash Reserves, Powers Operations Strategies

MCUR’s $10 Million Financing Triples Cash Reserves, Powers Operations Strategies

2021-01-21
Mind Cure announces a CAD$10 million bought deal financing at a unit price of CAD$0.60. Proceeds will be directed toward product research development and related tech initiatives like its iSTRYM digital therapeutics platform.

Mind Cure Establishes Psychedelic Compound Research Program

Compass Pathways Files For NASDAQ Listing: Psychedelics Game-Changer

The Psychedelics Revolution: From ‘War on Drugs’ To Funding Psychedelic Drug Research

Eleusis Looks For Alzheimer’s Breakthrough With Micro-Dosed LSD

Psychedelic Stocks
NEWS
INDUSTRY
INVESTING
COMPANIES
EXCLUSIVE

Newsletter

Get The Seed Investor straight to your email.

Copyright © 2016-2022, The Seed Investor | About | Contact | Advertise | Privacy Policy | Disclaimer
Powered by StructureCMS
The Seed Investor